Current Treatment of Pediatric Bladder and Prostate Rhabdomyosarcoma

Current Treatment of Pediatric Bladder and Prostate Rhabdomyosarcoma Purpose of Review Rhabdomyosarcoma (RMS) is the most common sarcoma diagnosed in the first 20 years of life; bladder/ prostate (BP) RMS accounts for 5% of all cases. Through efforts from multiple cooperative study groups, survival has improved significantly. This article aims to review the complex RMS classification system and treatment of BP RMS, with a focus on developing aspects of treatment. Recent Findings Recent advancements in technology are responsible for most of the progress in RMS treatment. PET-CT scanning has been shown to be superior to conventional metastatic workup. The use of proton beam therapy and brachytherapy to reduce the side effects of radiation is also showing promise. Summary All cooperative oncology groups agree on surgical biopsy for diagnosis and staging of BP RMS. Patients are then grouped and risk classified before receiving chemotherapy. Regardless of local control strategy, oncologic outcomes appear to be similar for BP RMS. Alternative treatment strategies, which remain unproven, include brachytherapy and proton therapy. . . . . Keywords Rhabdomyosarcoma Bladder Prostate Long-term outcomes Treatment morbidity Introduction cooperative groups, with the International Society for Pediatric Oncology (SIOP) being largest. Survival for all sites Rhabdomyosarcoma (RMS) is the most common pediatric of RMS has http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Urology Reports Springer Journals

Current Treatment of Pediatric Bladder and Prostate Rhabdomyosarcoma

Loading next page...
 
/lp/springer_journal/current-treatment-of-pediatric-bladder-and-prostate-rhabdomyosarcoma-Rzc2SfLW7A
Publisher
Springer US
Copyright
Copyright © 2018 by Springer Science+Business Media, LLC, part of Springer Nature
Subject
Medicine & Public Health; Urology; Nephrology
ISSN
1527-2737
eISSN
1534-6285
D.O.I.
10.1007/s11934-018-0761-8
Publisher site
See Article on Publisher Site

Abstract

Purpose of Review Rhabdomyosarcoma (RMS) is the most common sarcoma diagnosed in the first 20 years of life; bladder/ prostate (BP) RMS accounts for 5% of all cases. Through efforts from multiple cooperative study groups, survival has improved significantly. This article aims to review the complex RMS classification system and treatment of BP RMS, with a focus on developing aspects of treatment. Recent Findings Recent advancements in technology are responsible for most of the progress in RMS treatment. PET-CT scanning has been shown to be superior to conventional metastatic workup. The use of proton beam therapy and brachytherapy to reduce the side effects of radiation is also showing promise. Summary All cooperative oncology groups agree on surgical biopsy for diagnosis and staging of BP RMS. Patients are then grouped and risk classified before receiving chemotherapy. Regardless of local control strategy, oncologic outcomes appear to be similar for BP RMS. Alternative treatment strategies, which remain unproven, include brachytherapy and proton therapy. . . . . Keywords Rhabdomyosarcoma Bladder Prostate Long-term outcomes Treatment morbidity Introduction cooperative groups, with the International Society for Pediatric Oncology (SIOP) being largest. Survival for all sites Rhabdomyosarcoma (RMS) is the most common pediatric of RMS has

Journal

Current Urology ReportsSpringer Journals

Published: Feb 22, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off